Chen Yi, Cai Zhiyou, Ke Zunyu
Department of Neurology, Renmin Hospital, Hubei University of Medicine, Shiyan Renmin Hospital, Shiyan, Hubei Province, China.
Neurologist. 2017 Jul;22(4):120-126. doi: 10.1097/NRL.0000000000000136.
Accumulating research substantiates the statement that inflammation plays an important role in the development of stroke. Both proinflammatory and anti-inflammatory mediators are involved in the pathogenesis of stroke, an imbalance of which leads to inflammation. Anti-inflammation is a kind of hopeful strategy for the prevention and treatment of stroke. Substantial studies have demonstrated that minocycline, a second-generation semisynthetic antibiotic belonging to the tetracycline family, can inhibit neuroinflammation, inflammatory mediators and microglia activation, and improve neurological outcome. Experimental and clinical data have found the preclinical and clinical potential of minocycline in the treatment of stroke due to its anti-inflammation properties and anti-inflammation-induced pathogeneses, including antioxidative stress, antiapoptosis, inhibiting leukocyte migration and microglial activation, and decreasing matrix metalloproteinases activity. Hence, it suggests a great future for minocycline in the therapeutics of stroke that diminish the inflammatory progress of stroke.
越来越多的研究证实了炎症在中风发展过程中起重要作用这一说法。促炎和抗炎介质均参与中风的发病机制，两者失衡会导致炎症。抗炎是预防和治疗中风的一种有前景的策略。大量研究表明，米诺环素是一种属于四环素类的第二代半合成抗生素，可抑制神经炎症、炎症介质及小胶质细胞激活，并改善神经功能结局。实验和临床数据已发现米诺环素因其抗炎特性及抗炎诱导的发病机制（包括抗氧化应激、抗凋亡、抑制白细胞迁移和小胶质细胞激活以及降低基质金属蛋白酶活性）在中风治疗方面具有临床前和临床潜力。因此，米诺环素在减轻中风炎症进程的中风治疗中显示出广阔的前景。
